Program 2022
Monday, May 2, 2022
12:00-13:00 | General Assembly (by invitation only) Room Sydney |
12:30 | Registration opens Entrance |
13:00-14:00 | Press Conference Room Rio |
13:00-18:00 | Partnering and Global Village with Round Table Discussions throughout the day Room San Francisco |
13:00-19:00 | Exhibition throughout the day Foyer 2nd and 3rd Floor |
14:00-15:30 | Plenary Session Room Sydney |
15:15-15:45 | Coffee Break |
15:30-18:30 | Parallel Tracks |
15:30-18:30 Advanced Biotech Companies (Room Rio)
Moderator: Daniel Chancellor
15:30 – 15:45
15:45 – 16:00 16:00 – 16:15 16:15 – 16:30 16:30 – 16:45 16:45 – 17:00 17:00 – 17:15 17:15 – 17:30 17:30 – 17:45 17:45 – 18:00 18:00 – 18:15 18:15 – 18:30 |
Pharma Intelligence
break |
presented by
15:30-17:45 Emerging Biotech Companies (Room Singapore)
Moderator: Dominik Escher, Pureos Bioventures
15:30 – 15:45
15:45 – 16:00 16:00 – 16:15 16:15 – 16:30 16:30 – 16:45 16:45 – 17:00 17:00 – 17:15 17:15 – 17:30 17:30 – 17:45 |
Pureos Bioventures |
presented by
15:30-17:00 Clinical Stage Biotech Companies (Room Osaka/Samarkand)
15:30 – 15:45
15:45 – 16:00 16:00 – 16:15 16:15 – 16:30 16:30 – 16:45 16:45 – 17:00 |
Rentschler Biopharma |
presented by
15:30-18:15 Panel Discussions I (Room Sydney)
15:30 – 16:15 | Panel 1: Early Clinical Development: Optimizing Your Data Strategy and Realizing the Value of In Silico Evidence |
presented by |
16:30 – 17:15 | Panel 2: Translating innovation into healthcare solutions: How can Switzerland leap ahead? | presented by |
17:30 – 18:15 | Panel 3: From Discovery through Development to Commercialization – Partnering to accelerate science | presented by |
15:30-18:15 Panel Discussions II (Room Montreal)
15:30 – 16:15 | Panel 4: Collaborate to Innovate: Swiss Research Organizations Partner with Industry for Success |
presented by |
16:30 – 17:15 | Panel 5: Sustainability across the pharmaceutical value chain | presented by Swiss Biotech Association |
17:30 – 18:15 | Panel 6: Accelerating drug development through an advanced manufacturing network | presented by Swiss Biotech Association |
17:45-18:30 Venture Pitch (Room Singapore)
17:45 – 18:30 | Discover the Venture Leaders Biotech opportunities
Successful Venture Leaders alumni Ulf Grawunder will share his experience in building and selling NBE Therapeutics, a 1.1 bn exit, followed by pitches of selected biotech startups.
|
presented by |
17:45 | Opening and Venture Leaders Biotech introduction | |
17:50 | Presentation by and discussion with alumni Ulf Grawunder: From start to 1 billion exit |
|
18:00 | SEED Biosciences | Isolate single cells reliably and cost-effectively |
18:04 | MaxWell Biosystems AG | High-Content electrophysiology platforms |
18:08 | EraCal Therapeutics AG | We develop the next generation anti-obesity drug |
18:12 | InterAx Biotech AG | Reinventing GPCR drug discovery |
18:16 | Adiposs | Imaging Body Fat – Saving Lives |
18:20 | Muvon Therapeutics | Cell therapy for the regeneration of skeletal muscle tissue |
18:24 | Closing word with Bertrand Ducrey , CEO Debiopharm |
18:00-19:00 | International Reception Room San Francisco |
18:30-21:00 | Evening Reception Foyer 2nd Floor sponsored by |
Tuesday, May 3, 2022
07:30 | Registration opens Entrance |
08:00-16:00 | Partnering and Global Village with Round Table Discussions throughout the day Room San Francisco |
09:00-16:00 | Exhibition throughout the day Foyer 2nd and 3rd Floor |
09:30-11:30 | Plenary Session Room Sydney |
11:30-12:30 | Lunch Foyer 2nd and 3rd Floor |
12:30-16:00 | Parallel Tracks |
12:30-14:45 Advanced Biotech Companies (Room Rio)
Moderator: Daniel Chancellor
12:30 – 12:45
12:45 – 13:00 13:00 – 13:15 13:15 – 13:30 13:30 – 13:45 13:45 – 14:00 14:00 – 14:15 14:15 – 14:30 14:30 – 14:45 |
Pharma Intelligence |
presented by
14:50-16:00 Clinical Stage Biotech Companies (Room Rio)
14:50 – 15:00
15:00 – 15:15 15:15 – 15:30 15:30 – 15:45 15:45 – 16:00 |
Rentschler Biopharma |
presented by
12:30-16:00 Emerging Biotech Companies (Room Singapore)
Moderator: Martin Münchbach, Pureos Bioventures
12:30 -12:45
12:45 – 13:00 13:00 – 13:15 13:15 – 13:30 13:30 – 13:45 13:45 – 14:00 14:00 – 14:15 14:15 – 14:30 14:30 – 14:45 14:45 – 15:00 15:00 – 15:15 15:15 – 15:30 15:30 – 15:45 15:45 – 16:00 |
CDR Life
Clemedi |
presented by
12:30-16:15 Panel Discussions III (Room Osaka/Samarkand)
12:30 – 13:15 | Panel 7: Waiver for Covid Patents: Bleak future for biopharma industry? |
presented by |
13:30 – 14:15 | Panel 8: The pathway of orphan drugs: From development to patient access in Switzerland | presented by |
14:30 – 15:15 | Panel 9: Making 3D cell-based technologies accessible and actionable – remaining challenges and potential solutions | presented by CSEM |
15:30 – 16:15 | Panel 10: RNA Drugs: Applications Beyond Vaccines | presented by Swiss Biotech Association |
12:30-16:15 Panel Discussions IV (Room Sydney)
12:30 – 13:15 | Panel 11: How vital is ESG reporting for biotech companies and their investors? |
presented by KPMG |
13:30 – 14:15 | Panel 12: Where can we improve the Swiss framework conditions? | presented by Swiss Biotech Association |
14:30 – 15:15 | Panel 13: Financing Swiss Biotech: From Grants to IPOs | presented by Swiss Biotech Association |
15:30 – 16:15 | Panel 14: Investments in Lifes Science Real Estate & The case of Shared Labs | presented by |
14:30-16:15 Panel Discussions V (Room Montreal)
14:30 – 15:15 | Panel 15: Talent Shortage – Our way to stand out | presented by |
15:30 – 16:15 | Panel 16: Attract & retain talents | presented by Swiss Biotech Association |
14:30-15:00 | Coffee Break |
16:00-18:00 | Evening Reception Foyer 2nd and 3rd Floor sponsored by |
More details will be announced soon. Subject to change without notice.